Nirsevimab: first approval
SJ Keam�- Drugs, 2023 - Springer
Nirsevimab (Beyfortus�), a long-acting intramuscular recombinant neutralising human
IgG1ĸ monoclonal antibody to the prefusion conformation of the respiratory syncytial virus�…
IgG1ĸ monoclonal antibody to the prefusion conformation of the respiratory syncytial virus�…
Respiratory syncytial virus is the leading cause of United States infant hospitalizations, 2009–2019: a study of the national (nationwide) inpatient sample
M Suh, N Movva, X Jiang, LC Bylsma…�- The Journal of�…, 2022 - academic.oup.com
Background This study describes leading causes of hospitalization, including respiratory
syncytial virus (RSV), in United States infants (< 1 year) from 2009 through 2019. Methods�…
syncytial virus (RSV), in United States infants (< 1 year) from 2009 through 2019. Methods�…
[HTML][HTML] Nirsevimab for prevention of hospitalizations due to RSV in infants
SB Drysdale, K Cathie, F Flamein, M Knuf…�- …�England Journal of�…, 2023 - Mass Medical Soc
Background The safety of the monoclonal antibody nirsevimab and the effect of nirsevimab
on hospitalizations for respiratory syncytial virus (RSV)–associated lower respiratory tract�…
on hospitalizations for respiratory syncytial virus (RSV)–associated lower respiratory tract�…
[HTML][HTML] Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on�…
JM Jones�- MMWR. Morbidity and mortality weekly report, 2023 - cdc.gov
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among US infants.
In July 2023, the Food and Drug Administration approved nirsevimab, a long-acting�…
In July 2023, the Food and Drug Administration approved nirsevimab, a long-acting�…
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with�…
Background In a phase 2b trial and the phase 3 MELODY trial, nirsevimab, an extended half-
life, monoclonal antibody against respiratory syncytial virus (RSV), protected healthy infants�…
life, monoclonal antibody against respiratory syncytial virus (RSV), protected healthy infants�…
Expected impact of universal immunization with nirsevimab against RSV-related outcomes and costs among all US infants in their first RSV season: a static model
A Kieffer, M Beuvelet, A Sardesai…�- The Journal of�…, 2022 - academic.oup.com
Background Respiratory syncytial virus (RSV) is associated with substantial morbidity in the
United States, especially among infants. Nirsevimab, an investigational long-acting�…
United States, especially among infants. Nirsevimab, an investigational long-acting�…
Antibodies to watch in 2023
H Kaplon, S Crescioli, A Chenoweth, J Visweswaraiah…�- MAbs, 2023 - Taylor & Francis
In this 14th installment of the annual Antibodies to Watch article series, we discuss key
events in commercial monoclonal antibody therapeutics development that occurred in 2022�…
events in commercial monoclonal antibody therapeutics development that occurred in 2022�…
[HTML][HTML] The road to approved vaccines for respiratory syncytial virus
TJ Ruckwardt�- NPJ vaccines, 2023 - nature.com
After decades of work, several interventions to prevent severe respiratory syncytial virus
(RSV) disease in high-risk infant and older adult populations have finally been approved�…
(RSV) disease in high-risk infant and older adult populations have finally been approved�…
RSV disease in infants and young children: Can we see a brighter future?
E Baraldi, G Checcucci Lisi, C Costantino…�- Human Vaccines &�…, 2022 - Taylor & Francis
Respiratory syncytial virus (RSV) is a highly contagious seasonal virus and the leading
cause of Lower Respiratory Tract Infections (LRTI), including pneumonia and bronchiolitis in�…
cause of Lower Respiratory Tract Infections (LRTI), including pneumonia and bronchiolitis in�…
Nirsevimab and hospitalization for RSV bronchiolitis
Z Assad, AS Romain, C Aupiais, M Shum…�- …�England Journal of�…, 2024 - Mass Medical Soc
Background Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis, resulting
in 3 million hospitalizations each year worldwide. Nirsevimab is a monoclonal antibody�…
in 3 million hospitalizations each year worldwide. Nirsevimab is a monoclonal antibody�…